Cohance Lifesciences submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year ended March 31, 2026. The filing outlines the company's environmental, social, and governance metrics following its integration into the Cohance platform.

The company reported a significant shift in its energy mix, raising its renewable energy consumption to 14% from 0.6% in the prior year. This transition was supported by solar power purchase agreements and on-site installations across its manufacturing facilities.

Environmental Performance

Cohance reported a reduction in absolute Scope 3 greenhouse gas emissions by approximately 6.4%. The company achieved Zero Liquid Discharge (ZLD) status at specific API and CDMO units, while effluents from other sites were treated before discharge to authorized third-party facilities.

Total waste generated increased to 28,823.13 metric tonnes from 18,360.84 metric tonnes in the previous year. However, waste recovery operations improved substantially, with 24,762 metric tonnes recovered through recycling, reuse, or other recovery methods compared to 14,353 metric tonnes previously.

Social and Governance Metrics

The company maintained a strong safety record with zero lost-time injuries, fatalities, or high-consequence work-related incidents reported during the year. Employee turnover for permanent staff stood at 17%, an increase from 14.1% in the prior year.

Regarding human rights, the company reported one complaint under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, which was investigated and resolved within the reporting period. No disciplinary actions were taken against directors or key managerial personnel for bribery or corruption.

What the Numbers Show

A notable divergence exists between the company's revenue performance and its resource intensity metrics. While revenue from operations declined to ₹2,030.50 crore from ₹2,504.43 crore, total energy consumption rose to 8,54,242 GJ from 7,84,146 GJ. This indicates that despite lower sales volume, the operational energy load increased, suggesting that recent capacity expansions or process changes may have outpaced efficiency gains in terms of absolute consumption during this period.

Cohance Lifesciences Limited has scheduled its eighth Annual General Meeting (AGM) for September 17, 2026. The event will be conducted through video conference or other audio-visual means.

The meeting aims to transact ordinary business items for the financial year ended March 31, 2026. Key agenda points include the adoption of standalone and consolidated financial statements. Shareholders will also vote on the reappointment of Ms. Shweta Jalan as a director liable to retire by rotation.

Meeting Schedule and Logistics

The AGM will commence at 4:00 pm on Thursday, September 17, 2026. The company has engaged KFin Technologies Limited to facilitate the remote e-voting process. Members holding shares as on the cut-off date of September 10, 2026, are eligible to vote.

Director Reappointment Details

Ms. Shweta Jalan, who brings over 25 years of experience in private equity, offers herself for reappointment. She currently serves as a Managing Partner at Advent and joined the board in November 2023. Her remuneration for this role is nil.

Ms. Jalan attended nine out of eleven board meetings held during FY26. She holds directorships in Svatantra Microfin Private Limited, Modenik Lifestyle Private Limited, and Coforge Limited. She resigned from Yes Bank Limited within the past three years.